C. difficile Infection: Changing Epidemiology and Management Paradigms

The incidence of Clostridium difficile infection (CDI) has been rising in hospitals, long-term care facilities, and within the community. Cases have been more severe with more complications, deaths, and higher healthcare-associated costs. With the emergence of a hypervirulent strain of C. difficile and the increasing prevalence of community-acquired CDI among healthy patients without traditional risk factors, the epidemiology of C. difficile has been evolving. This changing epidemiology requires a change in management. Taking into account new risk factors for CDI and growing subpopulations of affected individuals, diagnostic, treatment, and prevention approaches need to be adjusted.

[1]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[2]  D. Pardi,et al.  Clostridium difficile infection: new insights into management. , 2012, Mayo Clinic proceedings.

[3]  A. Robicsek,et al.  Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. , 2010, American journal of infection control.

[4]  Sandra Romero-Steiner,et al.  The Second International Conference on Women and Infectious Diseases , 2006 .

[5]  D. Pardi,et al.  The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings , 2010, Expert review of gastroenterology & hepatology.

[6]  M. Shrime,et al.  Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Bartlett,et al.  Historical perspectives on studies of Clostridium difficile and C. difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Kachrimanidou,et al.  Clostridium difficile Infection: A Comprehensive Review , 2011, Critical reviews in microbiology.

[9]  R. Cantón,et al.  Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  B. Limbago,et al.  Clostridium difficile in Retail Meat Products, USA, 2007 , 2009, Emerging infectious diseases.

[11]  J. Silva,et al.  Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. , 1981, The Journal of infectious diseases.

[12]  M. Wilcox.  Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[14]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[15]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[16]  J. O’Horo,et al.  The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  J. Marshall,et al.  Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. , 2012, Archives of internal medicine.

[18]  J. Weese,et al.  Clostridium difficile in Retail Ground Meat, Canada , 2007, Emerging infectious diseases.

[19]  D. Gerding,et al.  Toxin Gene Analysis of a Variant Strain ofClostridium difficile That Causes Human Clinical Disease , 2000, Infection and Immunity.

[20]  F. Lessa.  Community-associated Clostridium difficile infection: how real is it? , 2013, Anaerobe.

[21]  C. Woods,et al.  Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA , 2010, Infection.

[22]  C. Surawicz.  Clostridium Difficile Infection: Risk Factors, Diagnosis and Management , 2015, Current Treatment Options in Gastroenterology.

[23]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[24]  J. Boyce,et al.  Lack of Association Between the Increased Incidence of Clostridium difficile–Associated Disease and the Increasing Use of Alcohol-Based Hand Rubs , 2006, Infection Control & Hospital Epidemiology.

[25]  C. Luxemburger,et al.  Clostridium difficile: development of a novel candidate vaccine. , 2012, Vaccine.

[26]  Ashwin N Ananthakrishnan,et al.  Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections , 2013, The American Journal of Gastroenterology.

[27]  D. Pardi,et al.  Gastric acid suppression and outcomes from clostridium difficile infection: a population-based study , 2011, Gut.

[28]  C. Surawicz,et al.  Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond , 2013, Expert review of gastroenterology & hepatology.

[29]  G. Guyatt,et al.  Probiotics for the Prevention of Clostridium difficile–Associated Diarrhea , 2012, Annals of Internal Medicine.

[30]  Michael B Gravenor,et al.  Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial , 2013, The Lancet.

[31]  T. Eckmanns,et al.  Clostridium difficile Surveillance Trends, Saxony, Germany , 2008, Emerging Infectious Diseases.

[32]  A. Manges,et al.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Anne Elixhauser,et al.  Clostridium Difficile Infections (CDI) in Hospital Stays, 2009 , 2012 .

[34]  C. Surawicz.  Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. , 2003, Best practice & research. Clinical gastroenterology.

[35]  C. Donskey,et al.  Utility of a Commercial PCR Assay and a Clinical Prediction Rule for Detection of Toxigenic Clostridium difficile in Asymptomatic Carriers , 2013, Journal of Clinical Microbiology.

[36]  P. Malani,et al.  Diagnosis and treatment of Clostridium difficile in adults: a systematic review. , 2015, JAMA.

[37]  F. Gordin,et al.  Reduction in Nosocomial Transmission of Drug-Resistant Bacteria After Introduction of an Alcohol-Based Handrub , 2005, Infection Control & Hospital Epidemiology.

[38]  M. Owings,et al.  Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–2003 , 2006, Emerging Infectious Diseases.

[39]  C. Surawicz,et al.  Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics , 1999, Infection Control & Hospital Epidemiology.

[40]  A. Zinsmeister,et al.  The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study , 2012, The American Journal of Gastroenterology.

[41]  A. Gibb,et al.  A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections. , 2014, The Journal of infection.

[42]  T. Concannon,et al.  Epidemiology of Clostridium difficile Colitis in Hospitalized Patients with Inflammatory Bowel Diseases , 2009, Diseases of the colon and rectum.

[43]  Alexander Rodriguez-Palacios,et al.  Transmission of Clostridium difficile in foods. , 2013, Infectious disease clinics of North America.

[44]  J. Bodmer,et al.  Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. , 2014, Vaccine.

[45]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[46]  Fernanda C. Lessa,et al.  Current Status of Clostridium difficile Infection Epidemiology , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  C. Surawicz,et al.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  T. Horan,et al.  Recommendations for Surveillance of Clostridium difficile–Associated Disease , 2007, Infection Control & Hospital Epidemiology.

[49]  A. Gasbarrini,et al.  Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection , 2015, Alimentary pharmacology & therapeutics.

[50]  Roger Baxter,et al.  Treatment with monoclonal antibodies against Clostridium difficile toxins. , 2010, The New England journal of medicine.

[51]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[52]  M. Maley,et al.  Clostridium difficile Testing: Have We Got It Right? , 2012, Journal of Clinical Microbiology.

[53]  J. Weese,et al.  Disease transmission model for community-associated Clostridium difficile infection , 2010, Epidemiology and Infection.

[54]  L. Napolitano,et al.  Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. , 2014, Surgical infections.